Diseases / Tuberculosis
Tuberculosis
DiseaseTuberculosis is an infectious disease caused by Mycobacterium tuberculosis, primarily affecting the lungs but also capable of extrapulmonary involvement. It remains a major global health burden.
- Trials
- 1137
- Recruiting
- 87
- Completed
- 724
- With results
- 153
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Approved for marketing | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | — | — | — | — | 5 | — | — | — | — | — | 5 |
| Phase 1 | 2 | 4 | — | 3 | 126 | 7 | 3 | 1 | 8 | — | 154 |
| Phase 1/2 | — | 1 | 2 | 2 | 15 | 1 | 2 | — | 1 | — | 24 |
| Phase 2 | 12 | 4 | — | 3 | 103 | 8 | 2 | 1 | 13 | — | 146 |
| Phase 2/3 | 3 | — | — | 1 | 11 | 2 | 1 | — | 5 | — | 23 |
| Phase 3 | 9 | 6 | — | 4 | 56 | 2 | 2 | 1 | 9 | — | 89 |
| Phase 4 | 4 | 1 | — | 1 | 38 | 8 | 2 | — | 15 | — | 69 |
| Not applicable | 22 | 17 | 2 | 12 | 186 | 5 | 3 | 2 | 55 | — | 304 |
| Unknown | 35 | 16 | 3 | 6 | 184 | 7 | 5 | — | 66 | 1 | 323 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Tuberculosis | 5 | 154 | 24 | 146 | 23 | 89 | 69 | 304 | 323 | 1137 |
| Tuberculosis, Pulmonary | — | 16 | 4 | 34 | 4 | 15 | 2 | 26 | 24 | 125 |
| HIV Infections | — | 9 | 5 | 17 | 4 | 14 | 17 | 20 | 19 | 105 |
| Latent Tuberculosis | — | 1 | 1 | 2 | 2 | 7 | 9 | 25 | 43 | 90 |
| Acquired Immunodeficiency Syndrome | — | 5 | 1 | 2 | 4 | 5 | 12 | 37 | 16 | 82 |
| Tuberculosis, Multidrug-Resistant | — | 5 | — | 13 | 3 | 13 | 1 | 5 | 16 | 56 |
| Disease | — | 2 | — | — | — | 1 | 1 | 14 | 13 | 31 |
| Mycobacterium Infections | — | 4 | — | 4 | — | 2 | — | 5 | 8 | 23 |
| Lung Neoplasms | — | — | — | — | 1 | — | — | 9 | 8 | 18 |
| Extensively Drug-Resistant Tuberculosis | — | 1 | — | 4 | 1 | 5 | — | — | 6 | 17 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | National Institute of Allergy and Infectious Diseases (NIAID) | 77 | 8 |
| 2 | University of Oxford | 36 | 0 |
| 3 | Global Alliance for TB Drug Development | 26 | 4 |
| 4 | Johns Hopkins University | 25 | 2 |
| 5 | University of Cape Town | 22 | 5 |
| 6 | Centers for Disease Control and Prevention | 21 | 4 |
| 7 | Aeras | 20 | 0 |
| 8 | GlaxoSmithKline | 19 | 0 |
| 9 | National Taiwan University Hospital | 16 | 2 |
| 10 | Assistance Publique - Hôpitaux de Paris | 15 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Isoniazid | 113 |
| 2 | Rifampin | 83 |
| 3 | Pyrazinamide | 61 |
| 4 | Ethambutol | 45 |
| 5 | bedaquiline | 36 |
| 6 | Moxifloxacin | 33 |
| 7 | rifapentine | 30 |
| 8 | MVA 85A | 25 |
| 9 | pretomanid | 24 |
| 10 | efavirenz | 21 |
Evidence
- Results reported
- 21.1%153 of 724 completed
- Published
- 11.9%86 of 724 completed
- Primary endpoint met
- 47.5%47 of 99 analyses
- Median months to report
- 16
Documents disclosed
Trial profile
- Median enrollment
- 180
- Median duration
- 28.9months
- Countries
- 102
- Study sites
- 2643
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 24
- Phase 1
- 32
- Phase 1/2
- 71
- Phase 2
- 106
- Phase 2/3
- 220
- Phase 3
- 566
- Phase 4
- 200
- Not applicable
- 350
- Unknown
- 250
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Cape Town | South Africa | 113 |
| 2 | Kampala | Uganda | 65 |
| 3 | Johannesburg | South Africa | 52 |
| 4 | Durban | South Africa | 44 |
| 5 | Lusaka | Zambia | 37 |
| 6 | Rio de Janeiro | Brazil | 33 |
| 7 | Seoul | South Korea | 31 |
| 8 | New York | United States | 30 |
| 9 | London | United Kingdom | 27 |
| 10 | Oxford | United Kingdom | 27 |
Terminations
- Terminated
- 40
- Withdrawn
- 20
- Suspended
- 5
- Stopped for recruitment
- 1.1%13 of 1137 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT05091580 Suspended | Suspended | Interruption in funding; Planned restart: October 2026 | 2028-07-31 |
| NCT05330884 Suspended | Suspended | changes in protocol | 2027-12-31 |
| NCT05539989 Withdrawn | Withdrawn | The study is no longer moving forward due to the changing TB vaccine landscape. | 2026-12-31 |
| NCT06845358 Withdrawn | Withdrawn | Study not implemented due to funding. | 2026-09-01 |
| NCT03159364 Terminated | Terminated | 2026-07-31 | |
| NCT02605538 Withdrawn | Withdrawn | Time and resource deficiency at the Stockholm CF Center. | 2025-12-31 |
| NCT06191692 Withdrawn | Withdrawn | Lack of Rifapentine | 2025-12-30 |
| NCT04518228 Terminated | Terminated | The study was closed to accrual early based on Study Monitoring Committee review indicating that the study objectives had either been achieved or could not be met within a reasonable timeframe for the then-open arms. | 2025-07-10 |
| NCT04311502 Terminated | Terminated | Accrual was permanently closed due to futility in the experimental arm on June 22, 2023. Follow-up in the experimental arm was extended to 117 weeks. | 2025-06-24 |
| NCT05284812 Suspended | Suspended | It is planned to restart the clinical study after the completion of the clinical trial protocol modification. | 2024-12-31 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: